Correlations of changes from baseline in dactylitis and enthesitis scores with changes from baseline in other measures of disease activity at week 24 for patients in the guselkumab group
| Correlations with change in enthesitis score at week 24* | Correlations with change in dactylitis score at week 24† | |||
|---|---|---|---|---|
| r value | P value | r value | P value | |
| Swollen joint count (0–66) | 0.27 | 0.02 | 0.50 | <0.0001 |
| Tender joint count (0–68) | 0.37 | 0.001 | 0.38 | 0.004 |
| Patient’s assessment of pain (VAS, 0–100 mm) | 0.13 | 0.28 | 0.08 | 0.53 |
| Patient’s global assessment of disease activity (VAS, 0–100 mm) | 0.32 | 0.005 | 0.20 | 0.14 |
| Physician’s global assessment of disease activity (VAS, 0–100 mm) | 0.47 | <0.0001 | 0.10 | 0.47 |
| HAQ-DI score (0–3) | 0.13 | 0.28 | 0.33 | 0.01 |
| CRP, mg/dL | 0.11 | 0.33 | 0.13 | 0.34 |
| SF-36 PCS | −0.27 | 0.02 | −0.22 | 0.09 |
| SF-36 MCS | −0.35 | 0.002 | −0.21 | 0.12 |
| PASI | 0.18 | 0.13 | 0.01 | 0.95 |
*n=75.
†n=57.
CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI, Psoriasis area And Severity Index; SF-36 MCS/PCS, 36-item Short-form Health Survey Mental/Physical Component Summary; VAS, visual analog scale.